Takeda Pharmaceutical Company, Ltd, Ibaraki 300-4293, Japan.
Bioorg Med Chem. 2010 Jun 1;18(11):3841-59. doi: 10.1016/j.bmc.2010.04.036. Epub 2010 Apr 20.
GPR54 is a G protein-coupled receptor (GPCR) which was formerly an orphan receptor. Recent functional study of GPR54 revealed that the receptor has an essential role to modulate sex-hormones including GnRH. Though antagonists of GPR54 are expected to be novel drugs for sex-hormone dependent diseases such as prostate cancer or endometriosis, small molecule GPR54 antagonists have not been reported. We have synthesized a series of 2-acylamino-4,6-diphenylpyridines to identify potent GPR54 antagonists. Detailed structure-activity relationship studies led to compound 9l with an IC(50) value of 3.7nM in a GPR54 binding assay, and apparent antagonistic activity in a cellular functional assay.
GPR54 是一种 G 蛋白偶联受体(GPCR),以前是一种孤儿受体。最近对 GPR54 的功能研究表明,该受体在调节包括 GnRH 在内的性激素方面具有重要作用。尽管 GPR54 的拮抗剂有望成为前列腺癌或子宫内膜异位症等性激素依赖性疾病的新型药物,但尚未报道小分子 GPR54 拮抗剂。我们已经合成了一系列 2-酰氨基-4,6-二苯基吡啶,以鉴定有效的 GPR54 拮抗剂。详细的构效关系研究导致化合物 9l 在 GPR54 结合测定中具有 3.7nM 的 IC50 值,并且在细胞功能测定中具有明显的拮抗活性。